Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009

Inclusion Criteria:

Currently enrolled in the B2151009 clinical study and benefiting from treatment with gedatolisib in combination with other therapies as determined by the Investigator
Previously demonstrated compliance and are willing and able to comply with scheduled visits, treatment plans, and other study procedures
No evidence of progressive disease, as determined by the Investigator
Provide written informed consent prior to enrolling and receiving treatment

Exclusion Criteria:

Permanently discontinued from treatment in Study B2151009, or discontinued from Study B2151009 for any reason
Women who are pregnant, intend to become pregnant, or nursing